189 related articles for article (PubMed ID: 36626879)
21. Assessing treatment outcomes of chemoimmunotherapy in extensive-stage small cell lung cancer: an integrated clinical and radiomics approach.
Zhao J; He Y; Yang X; Tian P; Zeng L; Huang K; Zhao J; Zhou J; Zhu Y; Wang Q; Chen M; Li W; Gao Y; Zhang Y; Xia Y
J Immunother Cancer; 2023 Sep; 11(9):. PubMed ID: 37730276
[TBL] [Abstract][Full Text] [Related]
22. Prognostic Value of BRAF and KRAS Mutation in Relation to Colorectal Cancer Survival in Iranian Patients: Correlated to Microsatellite Instability.
Nazemalhosseini-Mojarad E; Kishani Farahani R; Mehrizi M; Baghaei K; Yaghoob Taleghani M; Golmohammadi M; Peyravian N; Ashtari S; Pourhoseingholi MA; Asadzadeh Aghdaei H; Zali MR
J Gastrointest Cancer; 2020 Mar; 51(1):53-62. PubMed ID: 30635874
[TBL] [Abstract][Full Text] [Related]
23. Association between microsatellite status and characteristics and outcomes of early-onset compared to late-onset rectal cancer.
Emile SH; Horesh N; Garoufalia Z; Gefen R; Zhou P; Strassmann V; Wexner SD
Int J Colorectal Dis; 2024 Mar; 39(1):43. PubMed ID: 38538931
[TBL] [Abstract][Full Text] [Related]
24. PD-1/PD-L1 Inhibitor Plus Chemotherapy Versus PD-1/PD-L1 Inhibitor in Microsatellite Instability Gastrointestinal Cancers: A Multicenter Retrospective Study.
Chen M; Wang Z; Liu Z; Deng T; Wang X; Chang Z; Zhang Q; Yang W; Liu N; Ji Z; Zhang X; Wang X; Peng Z; Li Y; Cao Y; Jin X; Lu H; Qu H; Tang Y; Xu C; Fang W; Zhang H; Yan D; Wang L; Li J; Zhang J; Wang Q; Xue L; Yin F; Han G; Cheng Z; Liu Q; Jin Y; Zhang Y; Li L; Cao B; Yao Y; Chen Z; Zou J; Ying J; Wei Q; Tian T; Zhao W; Li L; Zhang T; Song F; Ba YE; Li N; Gao H; Ji Y; Bao L; Zhao X; Cai J; Yuan Z; Shen L; Li J
JCO Precis Oncol; 2023 Mar; 7():e2200463. PubMed ID: 36996375
[TBL] [Abstract][Full Text] [Related]
25. Consequences of a high incidence of microsatellite instability and BRAF-mutated tumors: A population-based cohort of metastatic colorectal cancer patients.
Aasebø KØ; Dragomir A; Sundström M; Mezheyeuski A; Edqvist PH; Eide GE; Ponten F; Pfeiffer P; Glimelius B; Sorbye H
Cancer Med; 2019 Jul; 8(7):3623-3635. PubMed ID: 31070306
[TBL] [Abstract][Full Text] [Related]
26. Efficacy of immunotherapy in patients with oncogene-driven non-small-cell lung cancer: a systematic review and meta-analysis.
Chen J; Lu W; Chen M; Cai Z; Zhan P; Liu X; Zhu S; Ye M; Lv T; Lv J; Song Y; Wang D
Ther Adv Med Oncol; 2024; 16():17588359231225036. PubMed ID: 38420602
[TBL] [Abstract][Full Text] [Related]
27. Outcomes and a prognostic classifier in patients with microsatellite instability-high metastatic gastric cancer receiving PD-1 blockade.
Randon G; Aoki Y; Cohen R; Provenzano L; Nasca V; Klempner SJ; Maron SB; Cerantola R; Chao J; Fornaro L; Ferrari Bravo W; Ghelardi F; Ambrosini M; Manca P; Salati M; Kawazoe A; Zhu V; Cowzer D; Genovesi V; Lonardi S; Shitara K; André T; Pietrantonio F
J Immunother Cancer; 2023 Jun; 11(6):. PubMed ID: 37277193
[TBL] [Abstract][Full Text] [Related]
28. Comparative Effectiveness of Immune Checkpoint Inhibitors vs Chemotherapy in Patients With Metastatic Colorectal Cancer With Measures of Microsatellite Instability, Mismatch Repair, or Tumor Mutational Burden.
Quintanilha JCF; Graf RP; Fisher VA; Oxnard GR; Ellis H; Panarelli N; Lin DI; Li G; Huang RSP; Ross JS; Myer PA; Klempner SJ
JAMA Netw Open; 2023 Jan; 6(1):e2252244. PubMed ID: 36689222
[TBL] [Abstract][Full Text] [Related]
29. Clinicopathologic features and prognostic value of KRAS, NRAS and BRAF mutations and DNA mismatch repair status: A single-center retrospective study of 1,834 Chinese patients with Stage I-IV colorectal cancer.
Guo TA; Wu YC; Tan C; Jin YT; Sheng WQ; Cai SJ; Liu FQ; Xu Y
Int J Cancer; 2019 Sep; 145(6):1625-1634. PubMed ID: 31162857
[TBL] [Abstract][Full Text] [Related]
30. Effect of Combined Immune Checkpoint Inhibition vs Best Supportive Care Alone in Patients With Advanced Colorectal Cancer: The Canadian Cancer Trials Group CO.26 Study.
Chen EX; Jonker DJ; Loree JM; Kennecke HF; Berry SR; Couture F; Ahmad CE; Goffin JR; Kavan P; Harb M; Colwell B; Samimi S; Samson B; Abbas T; Aucoin N; Aubin F; Koski SL; Wei AC; Magoski NM; Tu D; O'Callaghan CJ
JAMA Oncol; 2020 Jun; 6(6):831-838. PubMed ID: 32379280
[TBL] [Abstract][Full Text] [Related]
31. Clinicopathologic features of synchronous colorectal carcinoma: A distinct subset arising from multiple sessile serrated adenomas and associated with high levels of microsatellite instability and favorable prognosis.
Hu H; Chang DT; Nikiforova MN; Kuan SF; Pai RK
Am J Surg Pathol; 2013 Nov; 37(11):1660-70. PubMed ID: 23887157
[TBL] [Abstract][Full Text] [Related]
32. Impact of molecular alterations and targeted therapy in appendiceal adenocarcinomas.
Raghav KP; Shetty AV; Kazmi SM; Zhang N; Morris J; Taggart M; Fournier K; Royal R; Mansfield P; Eng C; Wolff RA; Overman MJ
Oncologist; 2013; 18(12):1270-7. PubMed ID: 24149137
[TBL] [Abstract][Full Text] [Related]
33. The interaction between BRAF mutation and microsatellite instability (MSI) status in determining survival outcomes after adjuvant 5FU based chemotherapy in stage III colon cancer.
Chouhan H; Sammour T; Thomas ML; Moore JW
J Surg Oncol; 2018 Dec; 118(8):1311-1317. PubMed ID: 30399198
[TBL] [Abstract][Full Text] [Related]
34. Molecular Features of Resected Melanoma Brain Metastases, Clinical Outcomes, and Responses to Immunotherapy.
Vasudevan HN; Delley C; Chen WC; Mirchia K; Pan S; Shukla P; Aabedi AA; Nguyen MP; Morshed RA; Young JS; Boreta L; Fogh SE; Nakamura JL; Theodosopoulos PV; Phillips J; Hervey-Jumper SL; Daras M; Pike L; Aghi MK; Tsai K; Raleigh DR; Braunstein SE; Abate AR
JAMA Netw Open; 2023 Aug; 6(8):e2329186. PubMed ID: 37589977
[TBL] [Abstract][Full Text] [Related]
35. Neuroendocrine Differentiation, Microsatellite Instability, and Tumor-infiltrating Lymphocytes in Advanced Colorectal Cancer With BRAF Mutation.
Digiacomo N; Bolzacchini E; Veronesi G; Cerutti R; Sahnane N; Pinotti G; Bregni M; Artale S; Verusio C; Crivelli F; Capella C; Sessa F; Furlan D
Clin Colorectal Cancer; 2019 Jun; 18(2):e251-e260. PubMed ID: 30638691
[TBL] [Abstract][Full Text] [Related]
36. Prognostic Effect of BRAF and KRAS Mutations in Patients With Stage III Colon Cancer Treated With Leucovorin, Fluorouracil, and Oxaliplatin With or Without Cetuximab: A Post Hoc Analysis of the PETACC-8 Trial.
Taieb J; Zaanan A; Le Malicot K; Julié C; Blons H; Mineur L; Bennouna J; Tabernero J; Mini E; Folprecht G; Van Laethem JL; Lepage C; Emile JF; Laurent-Puig P
JAMA Oncol; 2016 May; 2(5):643-653. PubMed ID: 26768652
[TBL] [Abstract][Full Text] [Related]
37. BRAF mutations in colorectal cancer are associated with distinct clinical characteristics and worse prognosis.
Kalady MF; Dejulius KL; Sanchez JA; Jarrar A; Liu X; Manilich E; Skacel M; Church JM
Dis Colon Rectum; 2012 Feb; 55(2):128-33. PubMed ID: 22228154
[TBL] [Abstract][Full Text] [Related]
38. High-frequency microsatellite instability and BRAF mutation (V600E) in unselected Serbian patients with colorectal cancer.
Markovic S; Antic J; Dragicevic N; Hamelin R; Krivokapic Z
J Mol Histol; 2012 Apr; 43(2):137-43. PubMed ID: 22210186
[TBL] [Abstract][Full Text] [Related]
39. The prognostic significance of KRAS and BRAF mutation status in Korean colorectal cancer patients.
Won DD; Lee JI; Lee IK; Oh ST; Jung ES; Lee SH
BMC Cancer; 2017 Jun; 17(1):403. PubMed ID: 28583095
[TBL] [Abstract][Full Text] [Related]
40. Clinical meaning of BRAF mutation in Korean patients with advanced colorectal cancer.
Kim B; Park SJ; Cheon JH; Kim TI; Kim WH; Hong SP
World J Gastroenterol; 2014 Apr; 20(15):4370-6. PubMed ID: 24764675
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
